和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

未开盘 10-29 16:08:21

21.160

+0.060

+0.28%

最高21.460	最低21.020	成交量257.31万
今开21.100	昨收21.100	日振幅2.09%
总市值184.52亿	流通市值184.52亿	总股本8.72亿
成交额5,451万	换手率0.30%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":21.16,"timestamp":1793261301002,"preClose":21.1,"halted":0,"volume":2573058,"delay":0,"changeRate":0.0028436018957345363,"floatShares":872000000,"shares":872000000,"eps":4.079767452807984,"marketStatus":"未开盘","change":0.06,"latestTime":"10-29 16:08:21","open":21.1,"high":21.46,"low":21.02,"amount":54512556,"amplitude":0.020853,"askPrice":21.16,"askSize":10000,"bidPrice":21.14,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":0.15840512168714402,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793323800000},"marketStatusCode":0,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":21.1,"openAndCloseTimeList":[[1793237400000,1793246400000],[1793250000000,1793260800000]],"volumeRatio":0.5795670657121104,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2679696425","title":"【券商聚焦】东吴证券维持和黄医药（00013）增持评级 指赛沃替尼精准治疗布局前移","url":"https://stock-news.laohu8.com/highlight/detail?id=2679696425","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679696425?lang=zh_cn&edition=full","pubTime":"2026-10-29 13:42","pubTimestamp":1793252560,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，和黄医药 赛沃替尼联合奥希替尼两项阳性III期研究亮相2026年ESMO大会，精准治疗布局向一线前移，维持“增持”评级。联合组因AE终止治疗比例为14.8%，未发现新的安全性问题。研报指出，SANOVO支持MET检测价值从耐药后延伸至初诊治疗决策，与SAFFRON共同构成一线干预及耐药后治疗的III期证据，为赛沃替尼扩大用药人群提供支持。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994720","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","00013","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679454464","title":"和黄医药(00013.HK)：索乐匹尼布(sovleplenib)获FDA孤儿药资格认定用于治疗原发免疫性血小板减少症","url":"https://stock-news.laohu8.com/highlight/detail?id=2679454464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679454464?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:11","pubTimestamp":1793232674,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00013","BK1587","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146810588","title":"和黄医药（00013）索乐匹尼布获FDA孤儿药资格认定 用于治疗原发免疫性血小板减少症","url":"https://stock-news.laohu8.com/highlight/detail?id=1146810588","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146810588?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:05","pubTimestamp":1793232333,"startTime":"0","endTime":"0","summary":"本报讯 2026年10月29日，和黄医药（00013）公布，其自主研发的口服高选择性脾酪氨酸激酶（Syk）抑制剂索乐匹尼布（sovleplenib）获得美国食品药品监督管理局（FDA）授予的孤儿药资格，用于治疗原发免疫性血小板减少症（ITP）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678435258","title":"中金：维持和黄医药(00013.HK) 目标价28港元 评级“跑赢行业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2678435258","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678435258?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:10","pubTimestamp":1793153430,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1587","BK1588","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678267110","title":"和黄医药(00013)将举办专家解读会探讨赛沃替尼(savolitinib)治疗非小细胞肺癌的最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2678267110","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678267110?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:08","pubTimestamp":1793059702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，将与花旗环球金融亚洲有限公司联合举行面向分析师和投资者的线上专家解读会，以探讨近期于2026年欧洲肿瘤内科学会年会上公布的赛沃替尼用于治疗MET驱动的非小细胞肺癌的最新III期临床数据。本次讨论将由SANOVO研究的主要研究者吴一龙教授担任主讲嘉宾 ，就MET驱动的非小细胞肺癌的最新临床数据与治疗策略分享专业见解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00013","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106929241","title":"和黄医药（00013）11月5日携手花旗举办线上专家解读会 聚焦赛沃替尼III期新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1106929241","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106929241?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:06","pubTimestamp":1793059567,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司10月27日发布自愿性公告称，公司将携手花旗环球金融亚洲有限公司于2026年11月5日举办面向分析师和投资者的线上专家解读会，聚焦在2026年欧洲肿瘤内科学会年会上公布的赛沃替尼用于治疗MET驱动非小细胞肺癌的最新III期临床数据。会议时间为中国香港时间16时30分、格林尼治标准时间08时30分、美国东部时间03时30分。赛沃替尼由和黄医药与阿斯利康共同开发，并由阿斯利康负责商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114421659","title":"和黄医药（00013）ESMO 2026披露SANOVO III期结果：沃瑞沙®联合泰瑞沙®一线治疗EGFR突变伴MET过表达肺癌 将疾病进展或死亡风险降低44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114421659","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114421659?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:36","pubTimestamp":1793003803,"startTime":"0","endTime":"0","summary":"在高水平MET人群中，联合疗法将疾病进展或死亡风险降低55%，中位PFS分别为24.8个月对比11.1个月。\\n\\n公司表示，基于SANOVO III期研究结果，计划于2026年年底在中国提交沃瑞沙联合泰瑞沙用于EGFR突变且伴MET过表达的局部晚期或转移性NSCLC一线治疗的新适应症上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678001168","title":"和黄医药(00013.HK)于2026年欧洲肿瘤内科学会(ESMO)年会公布沃瑞沙®(ORPATHYS®)联合泰瑞沙®(TAGRISSO®)用于一线治疗EGFR突变肺癌的SANOVO III期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2678001168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678001168?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:33","pubTimestamp":1793003635,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00013","BK1587","BK1191","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678159626","title":"和黄医药肺癌靶向药耐药临床研究取得突破，耐药患者死亡风险降低32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678159626","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678159626?lang=zh_cn&edition=full","pubTime":"2026-10-26 13:17","pubTimestamp":1792991829,"startTime":"0","endTime":"0","summary":"10月26日，和黄医药宣布，其自主研发的赛沃替尼联合阿斯利康已上市的靶向药奥希替尼，在EGFR突变肺癌患者靶向药耐药后，将死亡风险降低32%，中位总生存期延长近5个月。这项全球III期临床试验研究结果已在欧洲肿瘤内科学会年会主席论坛公布，并同步发表于《新英格兰医学杂志》。EGFR突变肺癌是常见的一类肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610263907863161.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610263907863161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00013","BK1587","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678321701","title":"和黄医药(00013)：于2026年欧洲肿瘤内科学会(ESMO)年会公布SAFFRON全球III期研究数据并同步发表于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678321701","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678321701?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:29","pubTimestamp":1792974548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，和黄医药(中国)有限公司今日宣布SAFFRON全球III期研究的积极结果。上述结果已于西班牙马德里召开的2026年欧洲肿瘤内科学会年会的主席论坛环节公布，并同步发表于《新英格兰医学杂志》。在肿瘤学界顶级学术盛会和旗舰医学期刊上的重磅亮相，凸显了SAFFRON研究在重塑MET驱动型EGFR突变非小细胞肺癌治疗格局中的关键地位。沃瑞沙和泰瑞沙联合疗法组将中位OS延长了4.9个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1191","00013","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678132407","title":"和黄医药公布SAFFRON III期研究数据 沃瑞沙联合泰瑞沙降低死亡风险32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678132407","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678132407?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:28","pubTimestamp":1792974480,"startTime":"0","endTime":"0","summary":"10月26日，和黄医药(00013.HK)公布SAFFRON全球III期研究积极结果，数据于2026年ESMO年会公布并同步发表于《新英格兰医学杂志》。在EGFR突变非小细胞肺癌患者中，沃瑞沙®(赛沃替尼)和泰 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261026/c681062460.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261026/c681062460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1191","BK1588","00013","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165383878","title":"和黄医药（00013）公布SAFFRON全球Ⅲ期研究积极结果　沃瑞沙®联合泰瑞沙®显著延长PFS及OS","url":"https://stock-news.laohu8.com/highlight/detail?id=1165383878","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165383878?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:06","pubTimestamp":1792973178,"startTime":"0","endTime":"0","summary":"2026年10月26日，和黄医药公告披露，其与阿斯利康共同开发的MET抑制剂沃瑞沙联合第三代EGFR TKI泰瑞沙的全球Ⅲ期SAFFRON研究取得积极结果，并已在2026年欧洲肿瘤内科科学会年会主席论坛正式发布，同步发表于《新英格兰医学杂志》。本次SAFFRON研究针对一线或二线泰瑞沙治疗后出现疾病进展、伴高水平MET过表达或扩增的EGFR突变非小细胞肺癌患者，比较沃瑞沙联合泰瑞沙与铂类双药化疗的疗效与安全性。研究共纳入338名患者，其中联合疗法组171例，对照组167例。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678213384","title":"2026年欧洲肿瘤内科学会召开：32项中国相关研究入选突破性摘要 占总入选数逾三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2678213384","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678213384?lang=zh_cn&edition=full","pubTime":"2026-10-25 19:41","pubTimestamp":1792928460,"startTime":"0","endTime":"0","summary":"当地时间10月23日，全球肿瘤学领域最具影响力的学术会议之一2026年欧洲肿瘤内科学会（ESMO）年会在西班牙马德里举行。本届大会上，中国创新药表现受到关注。据爱建证券有限责任公司（以下简称“爱建证券”）的研报统计，在本届大会的最新突破性摘要（LBA）名单中，中国相关研究达到32项，占比超过三成（共96项LBA）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610253907268231.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610253907268231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","BD","BK4139","00013","BK4231","KURE","BK1587","BK4505","NETL","BK4080","TIL","BK1191","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677642431","title":"【券商聚焦】中泰国际：创新药与医疗AI技术出海捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2677642431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677642431?lang=zh_cn&edition=full","pubTime":"2026-10-21 13:28","pubTimestamp":1792560508,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，中国创新药企业继2026年上半年出海金额同比增加36%至1,200亿美元后，下半年仍然捷报频出。港股上市的企业中，9月恒瑞医药9月与诺和诺德达成总额最高26亿美元的授权协议后，创新药龙头翰森制药与AI技术平台开发商剂泰科技近日分别与礼来及罗氏达成战略合作。该机构重申聚焦创新药龙头观点，并看好中国AI制药新技术。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994121","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1807302812.USD","06160","01801","01093","IE00BZ08YS42.EUR","LU1008478684.HKD","07666","IE00BZ08YT58.USD","BK1574","LU2242644610.SGD","LU1226287875.USD","LU1188198961.HKD","LU1813983027.USD","LU0228659784.USD","MEDX","03692","LU1951186391.HKD","LNGR","BK1521","KCE","LU0149534421.HKD","KURE","SG9999004220.SGD","LU0067412154.USD","00013","06978","150261","BK1161","LU0072913022.USD","LU0244354667.USD","LU0140636845.USD","LU1831875114.USD","LU1023057109.AUD","LU0607220059.USD","LU0502904849.HKD","LU0359202008.SGD","IBBQ","LU2488822045.USD","LU0463099449.HKD","LU0828237510.HKD","159992","IE00B031HY20.USD","LU0455707207.USD","01276","LU1719994722.HKD","LU1226287792.SGD","LU2097828557.USD","IE00B5MMRT66.SGD","LU1303224171.USD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165592666","title":"和黄医药（00013）与葛兰素史克完成HMPL-A830中国以外地区独家许可交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1165592666","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165592666?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:16","pubTimestamp":1792541765,"startTime":"0","endTime":"0","summary":"2026年10月21日，和黄医药发布自愿性公告称，继满足包括反垄断审查在内的成交条件后，其附属公司和记黄埔医药（上海）有限公司已与GSK plc附属公司完成独家开发及许可协议的交割。协议授予GSK附属公司在中国内地、香港、澳门和台湾以外地区开发及商业化全球首创抗体靶向偶联药物候选药物HMPL-A830的权利。根据约定，和记黄埔医药（上海）有限公司将负责HMPL-A830的全球I期开发，GSK附属公司将在其区域内承担后续临床开发和商业化工作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677610829","title":"和黄医药(00013)与葛兰素史克的KRAS-EGFR抗体偶联疗法中国以外地区许可协议已完成交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2677610829","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677610829?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:08","pubTimestamp":1792541315,"startTime":"0","endTime":"0","summary":"协议授予该葛兰素史克附属公司除中国内地、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。结直肠癌、胰腺癌和肺癌是KRAS基因改变发生率最高的癌症类型，这些患者往往缺乏安全且持久的KRAS疗法。葛兰素史克的附属公司将负责其区域内的所有后续的临床开发和商业化活动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","BK1191","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","LU1188198961.HKD","01952","LU1152091754.HKD","LU2488822045.USD","LU1008478684.HKD","01177","02268","LU0979878070.USD","06978","LU1242518857.USD","IBBQ","LU0417516738.SGD","LU2476274720.SGD","02162","06990","BK1521","LNGR","BK1161","03692","LU0359201885.HKD","LU0196878994.USD","00013","LU0417516902.SGD","LU1242518931.SGD","LU1720050803.USD","BK1589","MEDX","06855","LU0043850808.USD","01276","LU0211977185.USD","KURE","02269","BK1610","LU0052750758.USD","09969","IE0008369823.USD","LU1226288170.HKD","02157","LU1794554557.SGD","BK1576","LU0348827113.USD","02228","LU2543165471.USD","LU1993786604.SGD","01093","LU0128522744.USD","LU0588546209.SGD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675629564","title":"港股异动 | 和黄医药(00013)盘中涨超6% 花旗指业务运营已见拐点 ATTC平台价值将显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2675629564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675629564?lang=zh_cn&edition=full","pubTime":"2026-10-16 15:54","pubTimestamp":1792137261,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药盘中涨超6%。截至发稿，涨3.92%，报22.28港元，成交额1.28亿港元。SAFFRON全球III期研究显示该联合疗法在无进展生存期和总生存期方面均展现出改善。花旗发布研报称，和黄医药业务营运已见来自创新、临床进展及销售复苏的拐点。该行认为，随著数据的披露或持续达成交易，ATTC平台的价值将变得更加具体。同时预期SAFFRON以及SANOVO将带来正面读出数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0203347892.USD","LU1201861249.SGD","LU1244550221.USD","BK4566","LU1244550494.USD","LU0106831901.USD","LU1668664300.SGD","BK4534","KCAI","LU2456880835.USD","LU0128525689.USD","LU0052756011.USD","00013","LU0310800965.SGD","LU0162691827.USD","LU0203345920.USD","LU2462157665.USD","BK4585","BK4559","LU2360032135.SGD","LU1506573853.SGD","LU2417539215.USD","LU0477156953.USD","LU0320765646.SGD","LU1074936037.SGD","LU0072461881.USD","LU1162221912.USD","IE00BSNM7G36.USD","IYF","LU0130517989.USD","LU0170899867.USD","BK4207","BK4504","BK1191","FTXO","LU2125154935.USD","LU2236285917.USD","VXUS","LU2125154778.USD","LU0314106906.USD","LU0648001328.SGD","LU1244550577.SGD","LU0980610538.SGD","TFNS","LU1366192091.USD","LU1791807156.HKD","LU0098860793.USD","BK4588","LU1267930227.SGD","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675552723","title":"和黄医药盘中涨超5%，联合疗法FDA上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675552723","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675552723?lang=zh_cn&edition=full","pubTime":"2026-10-16 10:20","pubTimestamp":1792117200,"startTime":"0","endTime":"0","summary":"10月16日，和黄医药(00013.HK)盘中涨超5%，截至10时8分，涨5.13%，报22.58港元/股，成交额4623.56万港元。消息面上，今年以来我国创新药对外授权交易总额已突破1200亿美元、同比增长36%，首 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261016/c680763629.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261016/c680763629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["IPOS","00013","BK4585","BK1588","BK4588","LABU","BK1191","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675397201","title":"花旗：和黄医药重申“买入/高风险”评级 目标价40.10港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675397201","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675397201?lang=zh_cn&edition=full","pubTime":"2026-10-14 12:17","pubTimestamp":1791951420,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。该行重申“买入/高风险”评级，目标价40.1港元。该行指出，抗体靶向偶联药物交易潜力的可扩展性，因其设计在抗体、定制连接子及差异化载荷方面均具备模块化特点。公司预期在2026年下半年至2027年将有新的ATTC及其他IND申请。该行认为，随着数据的披露或持续达成交易，ATTC平台的价值将变得更加具体；同时预期SAFFRON以及SANOVO将带来正面读出数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-10-14/doc-inivekpu1121789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00013","EWH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0528},{"period":"1month","weight":-0.0511},{"period":"3month","weight":0.1948},{"period":"6month","weight":0.0009},{"period":"1year","weight":-0.0824},{"period":"ytd","weight":0.0262}],"compareEarnings":[{"period":"1week","weight":0.001},{"period":"1month","weight":-0.0638},{"period":"3month","weight":-0.113},{"period":"6month","weight":-0.1093},{"period":"1year","weight":-0.1286},{"period":"ytd","weight":-0.1042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.004362},{"month":7,"riseRate":1,"avgChangeRate":0.132805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.047962},{"month":9,"riseRate":0.666667,"avgChangeRate":0.027356},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.047176},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}